Cite
Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection.
MLA
Tiruye, Tenaw, et al. “Medication-Based Comorbidity Measures and Prostate Cancer Treatment Selection.” Clinical Genitourinary Cancer, vol. 22, no. 2, Apr. 2024, p. 599–609.e2. EBSCOhost, https://doi.org/10.1016/j.clgc.2024.01.018.
APA
Tiruye, T., O’Callaghan, M., FitzGerald, L. M., Moretti, K., Jay, A., Higgs, B., Kichenadasse, G., Caughey, G., Roder, D., & Beckmann, K. (2024). Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection. Clinical Genitourinary Cancer, 22(2), 599–609.e2. https://doi.org/10.1016/j.clgc.2024.01.018
Chicago
Tiruye, Tenaw, Michael O’Callaghan, Liesel M. FitzGerald, Kim Moretti, Alex Jay, Braden Higgs, Ganessan Kichenadasse, Gillian Caughey, David Roder, and Kerri Beckmann. 2024. “Medication-Based Comorbidity Measures and Prostate Cancer Treatment Selection.” Clinical Genitourinary Cancer 22 (2): 599–609.e2. doi:10.1016/j.clgc.2024.01.018.